Welcome to our dedicated page for Polypid Ltd. news (Ticker: PYPD), a resource for investors and traders seeking the latest updates and insights on Polypid Ltd. stock.
PolyPid Ltd (PYPD) is a clinical-stage biopharmaceutical company advancing surgical care through its proprietary PLEX drug delivery platform. This page provides investors and industry professionals with timely updates on clinical developments, regulatory milestones, and corporate news directly impacting PolyPid's growth trajectory.
Access consolidated information on Phase 3 trial results for D-PLEX100 in surgical infection prevention, technology licensing agreements, and strategic pipeline expansions. Our news collection serves as a neutral, fact-based resource for tracking PolyPid's progress in transforming localized drug delivery.
Key updates include clinical trial data disclosures, FDA/EMA regulatory communications, and partnership announcements related to PLEX applications. Bookmark this page to monitor PolyPid's advancements in prolonged-release therapeutics and their potential impact on surgical outcomes and oncology care.
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced it will release its second quarter 2024 financial results and operational highlights on August 14, 2024, before the U.S. financial markets open. The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide a business update.
Interested parties can register for the conference call via a provided link, with registration recommended at least 5 minutes before the call starts. For those not planning to ask questions, listening via the webcast is suggested. Both conference call and webcast links are provided in the announcement.
PolyPid, a biopharma company, hosted a Key Opinion Leader event to address the increasing rates of Surgical Site Infections (SSIs) post-COVID and provided an update on its SHIELD II Phase 3 trial for D-PLEX100. The event highlighted the rising SSI rates, the significant cost to payers, and the potential of D-PLEX100 to reduce SSIs in colorectal surgeries. Approximately 250 of the planned 600 patients are enrolled in the SHIELD II trial, with unblinded interim analysis expected once 400 patients complete their 30-day follow-up. Top-line results are anticipated in Q1 2025.
PolyPid announced a virtual Key Opinion Leader (KOL) event on June 17, 2024, at 10:00 AM ET to discuss the unmet medical need in surgical site infections (SSIs). Charles E. Edmiston, Ph.D., an Emeritus Professor of Surgery at the Medical College of Wisconsin, will highlight the clinical and economic burden of SSIs and current practices for their prevention. The event will also provide an update on PolyPid's Phase 3 SHIELD II trial for D-PLEX100, a product aimed at preventing abdominal colorectal SSIs. During the event, PolyPid management will update on patient enrollment status. A live Q&A session with Professor Edmiston and the management team will follow.
PolyPid provided a corporate update and reported financial results for the first quarter of 2024. The company enrolled over 200 patients in the SHIELD II Phase 3 trial for D-PLEX100 to prevent abdominal colorectal surgical site infections. The unblinded interim analysis is expected to be conducted after around 400 patients complete their 30-day follow-up, with top-line results anticipated in the second half of 2024. Additionally, PolyPid closed a private placement financing for $16 million, extending its cash runway beyond the planned analysis.
PolyPid (Nasdaq: PYPD) will participate in the Citizens JMP Life Sciences Conference in New York to present their late-stage biopharma innovations aimed at enhancing surgical outcomes. The event will be held from May 13 – 14, 2024, with a management presentation scheduled for May 13 at 2:30 PM ET.
PolyPid announced the enrollment of the 200th patient in the SHIELD II Phase 3 trial for D-PLEX100 to prevent surgical site infections. The study is one-third enrolled with top-line results expected in the second half of 2024. The company completed a $16 million financing and has the potential to secure an additional $19 million based on positive interim analysis results.
FAQ
What is the current stock price of Polypid Ltd. (PYPD)?
What is the market cap of Polypid Ltd. (PYPD)?
